Home > Healthcare > Pharmaceuticals > Finished Drug Form > barbiturate drugs market
Get a free sample of Barbiturate Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Barbiturate Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The barbiturate drugs industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced devices based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
Some of the eminent market participants operating in the barbiturate drugs industry include:
Johnson & Johnson, Merck & Co., Inc., Novartis AG, Par Pharmaceutical Companies, Inc., Pfizer Inc., Samarth Life Sciences Pvt Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Limited, are some of the major barbiturate drugs companies worldwide.
North America barbiturate drugs industry reached USD 191.6 million in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the presence of a well-developed healthcare infrastructure with modern facilities and sophisticated medical technology in the region.
The long-acting barbiturate segment recorded USD 200.4 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to their ability to provide sustained drug release over an extended period ensuring prolonged therapeutic effects.
Barbiturate drugs market size was USD 472.9 million in 2023 and is expected to register 3% CAGR from 2024-2032 owing to the surge in demand for innovative treatments and therapies to address the rising incidence of neurological disorders worldwide.